PT Central Proteina Prima Tbk

As of June 30, 2026, PT Central Proteina Prima Tbk carries a market capitalization of 2.98T, placing it among publicly traded companies globally. Its enterprise value stands at 4.47T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, PT Central Proteina Prima Tbk has 59.57B shares outstanding.

As of June 30, 2026, PT Central Proteina Prima Tbk trades at a trailing price-to-earnings ratio of 9.23. The price-to-sales ratio is 0.30, and the price-to-book ratio stands at 0.75.

As of June 30, 2026, PT Central Proteina Prima Tbk trades at an EV/EBITDA multiple of 6.20 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.82 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.47T versus a market cap of 2.98T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PT Central Proteina Prima Tbk maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.55, indicating elevated leverage, while an interest coverage ratio of 5.35 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, PT Central Proteina Prima Tbk posted a return on equity (ROE) of 8.37, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.73 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.61, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.40, useful for judging operating efficiency across full business cycles. The company generates approximately 5.56B in revenue per employee across its workforce of 1,803.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.96 indicates how many times PT Central Proteina Prima Tbk sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PT Central Proteina Prima Tbk recorded 186.71B in income tax expense. That works out to an effective tax rate of 36.63, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 509.65B, leaving 322.57B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, PT Central Proteina Prima Tbk's stock has declined approximately 42.86% over the past 52 weeks. The 50-day moving average sits at 45.78, while the 200-day moving average is 54.56.

Over the twelve months ended June 30, 2026, PT Central Proteina Prima Tbk generated 10.03T in revenue and converted that into 322.57B in net income, yielding earnings per share of 5.42. EBITDA reached 721.16B, while operating income came in at 745.56B.

As of June 30, 2026, PT Central Proteina Prima Tbk holds 83.88B in cash and equivalents against 1.58T in total debt, resulting in a net debt position of 1.40T. Total book value stands at 3.98T, with working capital of 477.14B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, PT Central Proteina Prima Tbk posted a gross margin of 19.22, reflecting its pricing power and cost economics. The operating margin of 7.43 and net profit margin of 3.22 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield reaches 6.95, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PT Central Proteina Prima Tbk shareholders.

As of June 30, 2026, PT Central Proteina Prima Tbk has an Altman Z-Score of 1.91, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.